Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03197779 · ClinicalTrials.gov registry record · Phase 1
A Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-962212 in Healthy Subjects
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 691
- Enrollment target
NCT03197779 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 691 participants.
The verdict
NCT03197779, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 691 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics following increasing doses of 2 h (Part A) and 5 day (Part B) continuous IV infusions of BMS-962212 in healthy subjects across the expected pharmacodynamic dose range.
Interventions
- OTHER Placebo
- DRUG Aspirin
- DRUG BMS-962212
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 691 participants |
| Start Date | 2013-11-18 |
| Est. Completion | 2017-01-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03197779
The ClinicalTrials.gov registry entry for NCT03197779 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 691 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03197779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03197779 about?
NCT03197779 is a clinical study titled "A Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-962212 in Healthy Subjects". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics following increasing doses of 2 h (Part A) and 5 day (Part B) continuous IV infusions of BMS-962212 in healthy subjects across the expected pharmacodynamic dose range.
What is the current status of trial NCT03197779?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 691 participants. The study started on 2013-11-18. Estimated completion is 2017-01-24.
What interventions are being tested in trial NCT03197779?
The interventions under investigation include: Placebo (OTHER), Aspirin (DRUG), BMS-962212 (DRUG).
Who is sponsoring clinical trial NCT03197779?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.